Ophthalmology pharma CEO time management across device and drug programs represents one of the most complex multi-dimensional management challenges in the medical products industry. CEOs of ophthalmology companies that develop and commercialize both pharmaceutical products (ophthalmic drugs regulated by FDA’s Center for Drug Evaluation and Research) and medical devices (surgical instruments, IOLs, diagnostic platforms, implantable drug delivery systems regulated by FDA’s Center for Devices and Radiological Health) must govern two distinct regulatory frameworks, two partially overlapping but distinct commercial infrastructures, and two sets of KOL relationships with meaningfully different characteristics.
Understanding the FDA CDER vs. CDRH Distinction in Ophthalmology
The regulatory division between drug and device oversight in ophthalmology creates concrete operational requirements that the CEO must understand directly. Ophthalmic drugs (anti-VEGF therapies, glaucoma medications, dry eye drugs, retinal disease treatments) are regulated under CDER’s NDA/BLA framework. Ophthalmic devices (phacoemulsification systems, femtosecond laser systems, intraocular lenses, tonometers, diagnostic imaging equipment, surgically implanted drug delivery devices) are regulated under CDRH’s 510(k) clearance or PMA approval framework.
The distinction matters for product development strategy, clinical evidence requirements, regulatory pathway selection, and post-approval compliance. CDER drug approvals require randomized controlled trials demonstrating safety and efficacy with a statistical significance standard. CDRH device approvals require demonstration of substantial equivalence to a predicate device (for 510(k)) or valid scientific evidence of safety and effectiveness (for PMA). The evidence standards, the submission formats, the review timelines, and the post-approval monitoring requirements all differ.
For ophthalmology companies with combination products (for example, a surgical implant that elutes a pharmaceutical compound), the regulatory pathway involves both centers through FDA’s Office of Combination Products, which designates the primary regulatory center based on the product’s primary mode of action. Combination products in ophthalmology (sustained-release implants delivering corticosteroids or anti-VEGF agents) have become commercially significant, and the CEO of a company developing combination products must understand the combination product regulatory framework at a level that allows governance of the regulatory strategy.
The CEO must invest time in ensuring that the regulatory affairs leadership for drug programs and the regulatory affairs leadership for device programs are coordinated within a coherent regulatory strategy, not operating as independent functional silos with separate FDA relationship portfolios.
Retinal Specialist KOL Relationships
The ophthalmology KOL community relevant to a pharmaceutical ophthalmology company is dominated by retinal specialists (vitreoretinal surgeons and medical retina physicians) for the most commercially significant product categories, including anti-VEGF therapies for wet AMD, diabetic macular edema, and retinal vein occlusion.
Retinal specialists are organized through the American Society of Retina Specialists (ASRS) and the Retina Society, with additional fellowship and subspecialty training programs concentrated at major academic ophthalmology departments. The CEO of an ophthalmology pharma company with retinal products must maintain a personal KOL portfolio focused on the academic retinal specialists who lead clinical research, shape treatment guidelines through the AAO Preferred Practice Patterns process, and participate in FDA advisory panels and scientific conferences.
The retinal specialist community is relatively small: there are approximately 3,000 to 3,500 practicing vitreoretinal surgeons in the United States. The top academic retinal specialists who meaningfully shape practice patterns number fewer than 100. The CEO can maintain a meaningful personal relationship with the 10 to 20 most influential retinal academic leaders, supplemented by the company’s medical science liaison infrastructure for broader KOL engagement.
Retinal specialist KOL relationships require investment in scientific credibility: these physicians are sophisticated researchers who evaluate clinical claims with rigor and who will not advocate for a product they do not believe is genuinely superior to alternatives. The CEO’s engagement with retinal KOLs should include participation in scientific advisory boards where genuine scientific exchange occurs, not simply commercial briefings.
Surgical vs. Pharmaceutical Commercial Infrastructure
The commercial infrastructure required for surgical ophthalmic devices differs fundamentally from the infrastructure required for pharmaceutical ophthalmic drugs, and the CEO must invest time in managing both while preventing the company from defaulting to a hybrid model that serves neither well.
Surgical device commercial infrastructure is built around: operating room account management (relationship with the ophthalmology department and OR procurement at hospital and ambulatory surgery center accounts), surgeon training programs (cataract surgeons and vitreoretinal surgeons require hands-on training for new surgical platforms and techniques), surgical procedure support (clinical field support in the OR during early adoption of new surgical technologies), and capital equipment sales processes (which involve multi-year contracts and budget cycle management unlike pharmaceutical sales).
Pharmaceutical ophthalmic commercial infrastructure is built around: retinal specialist and glaucoma specialist sales and medical education, medical benefit billing support for physician-administered biologics (anti-VEGF agents are typically billed under Part B/medical benefit, not Part D/pharmacy benefit), specialty pharmacy and limited distribution channel management for oral or topical ophthalmic drugs, and prior authorization support infrastructure for branded ophthalmic drugs.
Companies that attempt to build a single commercial organization to cover both surgical and pharmaceutical products typically build one that is adequate for neither. The CEO must make deliberate decisions about whether to staff separate commercial organizations for device and drug products, where to create shared infrastructure where it makes sense (customer analytics, market research), and how to manage the organizational complexity of two commercial teams calling on the same ophthalmologists for different product categories.
Reimbursement Navigation for Ophthalmic Products
Reimbursement in ophthalmology is distinctive because of the combination of medical benefit and pharmacy benefit products, the significant out-of-pocket market for elective procedures (cataract surgery with premium IOL upgrades, refractive surgery), and the complex coding environment for surgical procedures.
Anti-VEGF therapies (bevacizumab, ranibizumab, aflibercept, faricimab) are typically reimbursed under Medicare Part B as physician-administered drugs, with reimbursement tied to ASP-based rates that are set by CMS and updated quarterly. The CEO of a company with anti-VEGF products must invest time in Medicare Part B reimbursement policy monitoring, including the buy-and-bill economics that affect physician prescribing decisions and the potential impact of site-of-service policy changes that could shift administration from physician offices to hospital outpatient departments.
Surgical devices and premium IOLs for cataract surgery have a hybrid reimbursement model: the basic cataract surgery procedure is covered by Medicare, but premium IOL upgrades (toric, multifocal, extended depth of focus lenses) are not covered and are paid out-of-pocket by the patient. This out-of-pocket premium market has different commercial dynamics than the insurance-covered market, and the CEO must understand both.
The FDA’s ophthalmology drug approval pathway information provides context for the clinical evidence requirements that ophthalmology drug programs must meet before commercial reimbursement considerations apply.
Dry Eye and Glaucoma Commercial Dynamics
Beyond the retinal disease market, ophthalmology companies with dry eye and glaucoma products face commercial markets with distinct characteristics that the CEO must understand.
The dry eye market has grown substantially with the launches of branded cyclosporine formulations and lifitegrast, and has attracted significant investment in innovative formulations and drug delivery systems for meibomian gland disease. Dry eye is primarily managed by comprehensive ophthalmologists and optometrists, a much larger prescriber universe than retinal specialists, requiring a broader commercial infrastructure.
Glaucoma treatment is similarly managed by a broad prescriber base including comprehensive ophthalmologists and glaucoma specialists. The glaucoma drug market has extensive generic competition (most first-line prostaglandin analogs are generic), and branded glaucoma products must demonstrate clear differentiation from generic alternatives to achieve formulary coverage.
For context on how ophthalmology CEOs manage the overall enterprise across multiple commercial programs, time management for specialty pharmaceutical CEOs provides relevant frameworks for managing a complex, multi-product ophthalmology portfolio.
Managing the Organizational Culture Gap Between Drug and Device Teams
Pharmaceutical and medical device organizational cultures have distinct characteristics that create management challenges when combined within a single company. Drug development organizations are accustomed to long timelines (10 to 15 years from discovery to approval), rigorous controlled trial evidence standards, and FDA review processes measured in years. Device development organizations are accustomed to faster iteration cycles, clinical evidence standards that are less stringent for many products, and more direct market feedback through commercial use.
The CEO must invest time in bridging these cultural differences through explicit organizational design (clear role definitions, cross-functional coordination mechanisms) and leadership communication that acknowledges and respects both cultures rather than positioning one as superior to the other.
Conclusion: Ophthalmology Pharma CEO Time Management as Integration Mastery
Ophthalmology pharma CEO time management across device and drug programs is a discipline of integration: integrating FDA CDER and CDRH regulatory frameworks under coherent strategy, integrating surgical and pharmaceutical commercial organizations with appropriate separation, integrating retinal specialist and surgical KOL relationships within a coordinated medical affairs program, and integrating medical benefit and pharmacy benefit reimbursement approaches within a single market access strategy.
CEOs who master this integration build ophthalmology companies that serve the full needs of the ophthalmology community, from the clinic to the operating room, with products and commercial infrastructure appropriate to each context. That integrated capability is the competitive differentiator that distinguishes the best ophthalmology companies from their more narrowly positioned competitors.
Related Reading
For further context, explore How Biopharma CEOs Manage Time During Merger and Acquisition Due Diligence and How Biosimilar Company CEOs Manage Time Across Development and Market Access.